1. Modelling psychosis

   • H. Valerie Curran
   • Deepak Cyril D’Souza
   • Paul Fletcher

   Editorial 16 September 2009 Pages: 513 - 514

2. From drugs to deprivation: a Bayesian framework for understanding models of psychosis

   • P. R. Corlett
   • C. D. Frith
   • P. C. Fletcher

   Review Open access 28 May 2009 Pages: 515 - 530

   

3. Role of cannabis and endocannabinoids in the genesis of schizophrenia

   • Emilio Fernandez-Espejo
   • Maria-Paz Viveros
   • Fernando Rodriguez de Fonseca

   Review 24 July 2009 Pages: 531 - 549

   

4. The endocannabinoid system as a target for modelling psychosis

   • Dagmar Koethe
   • Carolin Hoyer
   • F. Markus Leweke

   Review 16 June 2009 Pages: 551 - 561

5. Superstitious conditioning as a model of delusion formation following chronic but not acute ketamine in humans

   • Tom P. Freeman
   • Celia J. A. Morgan
   • H. Valerie Curran

   Original Investigation 13 May 2009 Pages: 563 - 573

   

6. Modeling “psychosis” in vitro by inducing disordered neuronal network activity in cortical brain slices

   • George K. Aghajanian

   Review Open access 25 February 2009 Pages: 575 - 585

   

7. Prenatal exposure to infection: a primary mechanism for abnormal dopaminergic development in schizophrenia

   • Urs Meyer
   • Joram Feldon

   Review 11 March 2009 Pages: 587 - 602

   

8. The amphetamine sensitization model of schizophrenia: relevance beyond psychotic symptoms?

   • Daria Peleg-Raibstein
   • Benjamin K. Yee
   • Jonas Hauser

   Review 27 March 2009 Pages: 603 - 621

   

9. Long-term effects of neonatal MK-801 treatment on prepulse inhibition in young adult rats

   • Takashi Uehara
   • Tomiki Sumiyoshi
   • Masayoshi Kurachi

   Original Investigation 16 April 2009 Pages: 623 - 630

   

10. Reversal of cognitive deficits by an ampakine (CX516) and sertindole in two animal models of schizophrenia—sub-chronic and early postnatal PCP treatment in attentional set-shifting

    • Brian Villumsen Broberg
    • Birte Yding Glenthøj
    • Christina Kurre Olsen

    Original Investigation 24 April 2009 Pages: 631 - 640

    

11. Combined administration of an mGlu2/3 receptor agonist and a 5-HT_2A receptor antagonist markedly attenuate the psychomotor-activating and neurochemical effects of psychostimulants

    • Jason M. Uslaner
    • Sean M. Smith
    • Pete H. Hutson

    Original Investigation 26 August 2009 Pages: 641 - 651

    

12. Cognitive effects of psychotomimetic drugs in rats discriminating number cues

    • C. B. Willmore
    • D. M. Krall
    • G. I. Elmer

    Original Investigation 09 October 2008 Pages: 653 - 664

    

13. Serotonergic lesions of the dorsal hippocampus differentially modulate locomotor hyperactivity induced by drugs of abuse in rats: implications for schizophrenia

    • Wendy Adams
    • Scott Ayton
    • Maarten van den Buuse

    Original Investigation 23 July 2009 Pages: 665 - 676

    

14. Are DBA/2 mice associated with schizophrenia-like endophenotypes? A behavioural contrast with C57BL/6 mice

    • Philipp Singer
    • Joram Feldon
    • Benjamin K. Yee

    Original Investigation 30 May 2009 Pages: 677 - 698

    

15. Asenapine effects in animal models of psychosis and cognitive function

    • Hugh M. Marston
    • Jared W. Young
    • Mohammed Shahid

    Original Investigation Open access 22 May 2009 Pages: 699 - 714

    

16. The d-amphetamine-treated Göttingen miniature pig: an animal model for assessing behavioral effects of antipsychotics

    • F. Josef van der Staay
    • Bruno Pouzet
    • Teun Schuurman

    Original Investigation Open access 23 July 2009 Pages: 715 - 729

    

17. Disruption of latent inhibition induced by ovariectomy can be reversed by estradiol and clozapine as well as by co-administration of haloperidol with estradiol but not by haloperidol alone

    • Michal Arad
    • Ina Weiner

    Original Investigation 25 January 2009 Pages: 731 - 740